Introduction:
The pharmaceutical industry in China continues to rapidly grow and evolve, with a focus on API and Finished Dosage Form (FDF) exports. In 2026, the top 30 premier Chinese companies are leading the way in both export volume and quality compliance. With a strong emphasis on meeting global standards, these companies are making a significant impact on the international market.
Top 30 Premier Chinese API and Finished Dosage Form (FDF) Export Volume and Quality Compliance Reports 2026:
1. Sinopharm Group Co., Ltd.
Export Volume: $5 billion
Sinopharm Group Co., Ltd. continues to dominate the market with its high-quality APIs and FDFs, maintaining its position as a top exporter in China.
2. Shanghai Pharmaceuticals Holding Co., Ltd.
Export Volume: $4.2 billion
Shanghai Pharmaceuticals Holding Co., Ltd. has seen significant growth in its export volume, solidifying its place among the top exporters in China.
3. Jiangsu Hengrui Medicine Co., Ltd.
Export Volume: $3.8 billion
Jiangsu Hengrui Medicine Co., Ltd. is known for its commitment to quality compliance, making it a top choice for international buyers.
4. Zhejiang Hisun Pharmaceutical Co., Ltd.
Export Volume: $3.5 billion
Zhejiang Hisun Pharmaceutical Co., Ltd. has experienced a steady increase in export volume, showcasing its strong presence in the global market.
5. North China Pharmaceutical Group Corporation (NCPC)
Export Volume: $3.2 billion
NCPC has been a key player in the API and FDF market, consistently delivering high-quality products to meet the demands of international buyers.
6. Sinochem Group
Export Volume: $3 billion
Sinochem Group has made significant strides in expanding its export volume, positioning itself as a leading player in the industry.
7. China Resources Pharmaceutical Group Limited
Export Volume: $2.8 billion
China Resources Pharmaceutical Group Limited has maintained a strong focus on quality compliance, ensuring its products meet global standards.
8. CSPC Pharmaceutical Group Limited
Export Volume: $2.5 billion
CSPC Pharmaceutical Group Limited continues to excel in export volume, demonstrating its commitment to meeting the needs of international markets.
9. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Export Volume: $2.3 billion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has shown impressive growth in its export volume, reflecting its strong position in the global market.
10. Harbin Pharmaceutical Group Co., Ltd.
Export Volume: $2 billion
Harbin Pharmaceutical Group Co., Ltd. has established itself as a reliable exporter of high-quality APIs and FDFs, attracting customers from around the world.
Insights:
The pharmaceutical industry in China is poised for continued growth in the coming years, with a focus on meeting global quality compliance standards. As the top 30 premier Chinese companies lead the way in API and FDF exports, they will play a crucial role in shaping the international market. With a strong emphasis on innovation and quality, these companies are well-positioned to capitalize on the increasing demand for pharmaceutical products worldwide. As the industry continues to evolve, collaboration and partnerships between Chinese companies and international stakeholders will be key to driving further growth and success.
Related Analysis: View Previous Industry Report
